Literature DB >> 19747478

Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion.

Anitha S John1, Xioulong Hu, Vicki L Rothman, George P Tuszynski.   

Abstract

Thrombospondin-1 (TSP-1), a matrix-bound adhesive glycoprotein, has been shown to modulate tumor progression. We previously demonstrated that TSP-1 up-regulates matrix metalloproteinases MMP-2 and MMP-9. Our studies suggested that the balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs) is a key determinant in tumor cell invasion. We now report that TSP-1 up-regulates TIMP-1 expression in both human breast and prostate cancer cell lines. The effect of TSP-1 on TIMP-1 expression was examined in human breast adenocarcinoma cell lines (MDA-MB-231) and human prostate cancer cell lines (PC3-NI and PC3-ML) treated with exogenous TSP-1. TIMP-1 expression was also examined in TSP-1 stably transfected breast cancer cell line (MDA-MB-435). Northern and western blot analysis revealed TIMP-1 mRNA and TIMP-1 protein expression increased with increasing concentrations of TSP-1. This effect was inhibited by antibodies against the type I repeat domain of TSP-1 further suggesting that TSP-1 mediates TIMP-1 secretion. Inhibition of TSP-1 induced TIMP-1 levels increased tumor cell invasion. We conclude that TSP-1 is involved in influencing the critical balance between MMPs and their inhibitors, maintaining the controlled degradation of the extracellular matrix needed to support metastasis and our results may provide an explanation for the divergent activities reported for TSP-1 in tumor progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747478      PMCID: PMC2783349          DOI: 10.1016/j.yexmp.2009.09.002

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  23 in total

1.  Transforming growth factor-beta complexes with thrombospondin.

Authors:  J E Murphy-Ullrich; S Schultz-Cherry; M Höök
Journal:  Mol Biol Cell       Date:  1992-02       Impact factor: 4.138

2.  MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?

Authors:  Ann F Chambers
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

3.  Thrombospondin, a potentiator of tumor cell metastasis.

Authors:  G P Tuszynski; T B Gasic; V L Rothman; K A Knudsen; G J Gasic
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

Review 4.  The structural and functional properties of thrombospondin.

Authors:  J Lawler
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

5.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Authors:  D J Good; P J Polverini; F Rastinejad; M M Le Beau; R S Lemons; W A Frazier; N P Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells.

Authors:  D Albo; G P Tuszynski
Journal:  J Surg Res       Date:  2004-07       Impact factor: 2.192

7.  Thrombospondin-induced attachment and spreading of human squamous carcinoma cells.

Authors:  J Varani; V M Dixit; S E Fligiel; P E McKeever; T E Carey
Journal:  Exp Cell Res       Date:  1986-12       Impact factor: 3.905

8.  The interaction of human platelet thrombospondin with fibrinogen. Thrombospondin purification and specificity of interaction.

Authors:  G P Tuszynski; S Srivastava; H I Switalska; J C Holt; C S Cierniewski; S Niewiarowski
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

9.  Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.

Authors:  G P Tuszynski; V L Rothman; M Papale; B K Hamilton; J Eyal
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

10.  Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains.

Authors:  G Taraboletti; D D Roberts; L A Liotta
Journal:  J Cell Biol       Date:  1987-11       Impact factor: 10.539

View more
  11 in total

1.  A proteomics platform combining depletion, multi-lectin affinity chromatography (M-LAC), and isoelectric focusing to study the breast cancer proteome.

Authors:  Zhi Zeng; Marina Hincapie; Sharon J Pitteri; Samir Hanash; Joost Schalkwijk; Jason M Hogan; Hong Wang; William S Hancock
Journal:  Anal Chem       Date:  2011-05-23       Impact factor: 6.986

Review 2.  Thrombospondins as key regulators of synaptogenesis in the central nervous system.

Authors:  W Christopher Risher; Cagla Eroglu
Journal:  Matrix Biol       Date:  2012-01-21       Impact factor: 11.583

Review 3.  Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.

Authors:  Cynthia C Sprenger; Stephen R Plymate; May J Reed
Journal:  Int J Cancer       Date:  2010-10-08       Impact factor: 7.396

4.  Down-regulation of TIMP-1 inhibits cell migration, invasion, and metastatic colonization in lung adenocarcinoma.

Authors:  Ying-Hua Chang; Yi-Jen Chiu; Hung-Chi Cheng; Fang-Ju Liu; Wu-Wei Lai; Hsiao-Jen Chang; Pao-Chi Liao
Journal:  Tumour Biol       Date:  2015-01-13

5.  Myeloid-Derived TSP1 (Thrombospondin-1) Contributes to Abdominal Aortic Aneurysm Through Suppressing Tissue Inhibitor of Metalloproteinases-1.

Authors:  Huan Yang; Ting Zhou; Christine M Sorenson; Nader Sheibani; Bo Liu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-08       Impact factor: 8.311

Review 6.  Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects.

Authors:  Yasuyoshi Miyata; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2013-06-07       Impact factor: 5.923

Review 7.  Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Authors:  Marco Rusnati; Chiara Urbinati; Silvia Bonifacio; Marco Presta; Giulia Taraboletti
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-23

8.  EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.

Authors:  N Perez-Janices; I Blanco-Luquin; M T Tuñón; E Barba-Ramos; B Ibáñez; I Zazpe-Cenoz; M Martinez-Aguillo; B Hernandez; E Martínez-Lopez; A F Fernández; M R Mercado; T Cabada; D Escors; D Megias; D Guerrero-Setas
Journal:  Oncotarget       Date:  2015-01-01

9.  Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling.

Authors:  Gisela Nilsson; Marie Kannius-Janson
Journal:  BMC Cancer       Date:  2016-02-23       Impact factor: 4.430

10.  Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294.

Authors:  Alan Lap-Yin Pang; Alexandra C Title; Owen M Rennert
Journal:  Oncol Lett       Date:  2014-04-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.